



BioPharmica Limited

ASX Announcement – 22March, 2006

International Safety Certification for Drug Monitoring System

BioPharmica Ltd (ASX: BPH) announced today that the Brain Anaesthesia Response (BAR) monitor has been awarded with a key international medical safety standard certificate by Testing & Certification Australia. This certificate indicates compliance with the requirements of the International Electrotechnical Commission for conformity and certification of Electrical Equipment (IECEE) CB scheme.

The IECEE CB scheme is designed to remove the significant delays and costs of multiple testing and approval across countries and allows industry to be faster and cheaper to market with its products.

Put simply, a component or system manufactured to IECEE CB standards and manufactured in country A can be sold and used in 43 countries around the world.

The independent verification that the BAR system meets the safety standards for medical devices is a critical milestone in gaining access to international markets.

The BAR system was assessed against IEC standards that ensures that a certified product has been manufactured and type-tested to well established international medical safety standards.

An analysis on the validation trials with elective surgical patients conducted by leading specialists Dr David Liley and Associate Professor Kate Leslie at the Royal Melbourne Hospital is currently being completed, and a report on this trial will soon be released.

This trial was supported by funding, provided by the Australian and New Zealand College of Anaesthetists. The trial at Royal Melbourne Hospital involved patients who consented to being involved in the study as part of their elective surgery. While being anaesthetized patients had the electrical activity of their brain recorded from a set of electrodes placed on the forehead.

The data from these recordings were analyzed using sophisticated algorithms based on a biological understanding of the dynamics of human brain electrical activity discovered by Dr David Liley at Swinburne University of Technology in Melbourne, Australia.

International patent coverage is also pending in a number of Neuro-diagnostic settings that include detecting the early onset of degenerative diseases like Alzheimer's or Parkinson's as well as being used in drug discovery and evaluation associated with these conditions.

Further trials to extend the validation of the BAR Monitor are now being planned in a series of Australian hospitals. Discussions have also commenced with potential international collaborators

Dr S Gallagher

Managing Director
BioPharmica Ltd